ABSTRACT
Introduction: Decompensated liver disease caused by various modifiable and non-modifiable factors leads to the progression of cirrhosis, jaundice, bleeding varies and other complications which leads to high complications and mortality. This study was carried out to predict whether serum ferritin a marker of body iron stores and inflammation is a valid prognostic marker in advanced liver disease. Aim of the study: To study whether serum ferritin levels as an independent prognostic marker to predict the mortality of patients with decompensated liver disease. Materials and methods: It was a prospective and analytical study of 100 patients admitted to our hospital with DCLD and its complications. The study period was from August 2017 to July 2018. After informed consent patients were evaluated with laboratory investigations, clinical examination. Results: It was found that among enrolled 100 patients after getting informed consent, the majority were male patients but sex wise both female and male patients that P- the value of the comparison non-significant. This indicated that there was a low correlation between, LFT values with SF values. This also proved that high SF values were having a low association with LFT values which needs more investigation. Conclusion: Serum ferritin is one of the surrogate markers to predict prognosis in the patients of DCLD. Compared with a well established prognostic model like MELD score, to assess the mortality with SF level is statistically valid one. So, in future SF levels will be a one of the best screening independent prognostic markers in people with liver disease
ABSTRACT
In therapy of chronic hepatitis B, there are new and exciting developments in antivirals such as nucleotide analogues. Adefovir dipivoxil is an oral prodrug of adefovir, a nucleotide analogue of adenosine monophosphate. This agent has a potent in vitro and in vivo effect against herpes virus, retroviruses, and hepadnaviruses. In the hepatitis B virus (HBV) setting, adefovir dipivoxil inhibits both the wild type and lamivudine-resistant HBV strains. The safety profile of adefovir dipivoxil 10 mg is excellent, but higher doses can produce renal tubular damage, particularly when the drug is used for prolonged therapy. Adefovir dipivoxil is an important new addition to the current first-line treatments for HBeAg positive and negative chronic hepatitis B, as well as being rescue therapy for lamivudine-resistant HBV strains. It is also licensed for use in adults with decompensated liver disease, as well as compensated liver disease where there is evidence of active viral replication, persistently elevated serum alanine aminotransferase levels and active liver inflammation and fibrosis. However, a longer follow-up is needed to establish the long term safety and efficacy of adefovir dipivoxil in patients with chronic HBV infection.